Investors in biotech companies approach their investments with the mindset of praying or scratching a lottery ticket because the success rate of new drug development is extremely low, and the costs ...

Stability is a critical factor in drug formulation, with implications for product quality, lifecycle management, and ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Real-time ¹⁹F NMR enables faster, more efficient pharmaceutical synthesis by improving reaction monitoring, scalability, and ...

Functional packaging materials are increasingly designed to actively protect drug products, integrating moisture and impurity ...

After J.P. Morgan, biotech’s bold promises meet real-world challenges. In 2026, success starts with a CDMO partner who ...

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

Advances in biofabrication and 3D in vitro model systems are transforming biomedical research, drug development, and toxicity testing. However, despite ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy studies may prove ...

Thermo Fisher Scientific is acquiring Clario for roughly $8.9 billion, a major move to boost its clinical research services.